Get Updates

FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

Get Involved > HBOC Community > FORCE Blog

| More

FORCE Blog

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 1,111 other subscribers

Archives

PARP inhibitor research

November 14, 2016

Voices of FORCE: A BRCA Mutation is a Factor in Pancreatic Cancer

By Rona Greenberg Hereditary breast and ovarian cancer is part of my family history. My grandmother, Rebecca, for whom I am named, died from breast/ovarian cancer in1934; my mother was ten years old. My mother died from the same cancer in 1967; I was nineteen years old with three younger sisters. In 1997, I was … + read more

July 28, 2016

Metastatic Hereditary Breast Cancer Treatment Research: BROCADE 3 Study

By Heather Han, MD and Sue Friedman Metastatic Hereditary Breast Cancer Research There are major gaps in research, resources, and support for people with metastatic breast cancer – cancer that has spread beyond the breast and lymph nodes. A promising area of research is focusing on new treatments for hereditary metastatic breast cancer caused by … + read more

May 19, 2016

Updates in Research on Treating Hereditary Cancers

Note: This post which was originally published 08/4/15 was just updated on 05/19/16. In December 2014, the FDA approved the first targeted therapy for people with BRCA mutations. Lynparza, a type of medication known as a PARP inhibitor, was approved for women with a BRCA mutation to treat advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after … + read more

May 10, 2016

Experience with Oncology Clinical Trial Participation and Impact on Future Trial Design and Conduct

Note: Last year, TESARO, a pharmaceutical company developing a new PARP inhibitor for treatment of ovarian cancer and metastatic breast cancer, asked FORCE to help recruit previous clinical trial participants to join focus groups across the U.S. TESARO wanted to understand the patient experience to build clinical trials that are more responsive to patient needs. We … + read more

March 30, 2016

Update on Pancreatic Cancer Genetics Research

By Talia Golan, MD and Sue Friedman, DVM BRCA and pancreatic cancer The link between breast and ovarian cancer and BRCA mutations has been known since the 1990s. However, the awareness that these mutations also increase pancreatic cancer risk is more recent. If all patients with pancreatic cancer were tested for a BRCA1 or BRCA2 … + read more

March 17, 2016

Ovarian Cancer Survivors with a Negative Genetic Test Result in the Past May Benefit from Additional Genetic Counseling/Testing

KNOW MORE is a new campaign designed by FORCE to inform every woman diagnosed with ovarian, fallopian tube, and primary peritoneal cancer about national guidelines on genetic counseling and testing for inherited gene mutations. We kicked off the campaign by launching a brief survey to better understand how women with ovarian cancer make decisions around … + read more

March 3, 2016

OlympiA: A Landmark Breast Cancer PARP Inhibitor Clinical Trial

by Sue Friedman Great progress has been made since the identification of the BRCA1 and BRCA2 genes and their link to causing breast, ovarian, pancreatic and other cancers. Over the last two decades, researchers have studied how BRCA mutations cause cancer in an effort to develop new treatments. In December 2014, Lynparza, (olaparib), a type … + read more

February 18, 2016

What Every Woman with Ovarian Cancer Should Know: FORCE’S KNOW MORE Campaign and Survey

Increased awareness around BRCA genetic testing has helped people better understand their risk for cancer and options for lowering their risk. Less attention has focused on the importance of genetic testing for people who have already been diagnosed with cancer. This is particularly true for ovarian cancer survivors, because knowing your mutation status can change … + read more

September 27, 2015

Beyond Awareness: Working to Improve Outcomes for People Facing Hereditary Cancer

This week we mark National Hereditary Breast and Ovarian Cancer (HBOC) Week, and on Wednesday, National Previvor Day. This awareness campaign acknowledges the over one million people and families in the United States affected by hereditary cancer, due to a BRCA, PALB2, PTEN, ATM or other mutation linked to these cancers or a strong family history … + read more

September 3, 2015

Guest Blog: We All Deserve the Chance to Make Decisions About Our Futures

By Teri Woodhull Like most families in the FORCE community, cancer followed my family for generations. Breast cancer touched my mother, her mother, her mother’s mother, and my mother’s first cousin. And me. We knew it had to be more than a coincidence. My mother died at 46 of breast cancer. Her oncologist and other … + read more

August 9, 2015

Guest Blog: Attending ASCO as a Research Advocate

By Robin Karlin Thirty thousand health professionals, fabulous views of Lake Michigan and downtown Chicago, miles of escalators, fountains and crowded atriums, long lines at every Starbucks, session after session of the latest research and educational panels, and a fun evening at Shedd Aquarium. These were all part of my 2015 American Society of Clinical Oncology … + read more

April 13, 2015

Another Reason for People to Know Their BRCA Status

By sharing her BRCA status and news of her prophylactic surgeries with the world, Angelina Jolie Pitt has raised awareness about BRCA testing and hereditary cancer to new heights. Her op-eds have created the “the Angelina Effect,” a term describing how her celebrity has increased demand for these services. Still, many people who meet national … + read more

June 29, 2014

FDA Approval of Promising Targeted Therapy Likely Stalled Until More Research Studies are Completed

Wednesday, June 25, 2014 was a pivotal day for our community. It began with promise and ended with disappointment. For the first time ever, a treatment targeted for BRCA-associated cancers was considered for approval by the FDA. Yesterday the FDA’s Oncologic Drug Advisory Committee (ODAC) held a hearing to consider FDA approval of the drug … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered